Navigation Links
Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
Date:3/10/2008

PINE BROOK, N.J., March 10 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced the appointment of Robert Gundel, Ph.D., M.B.A., as Vice President of Research.

Elizabeth G. Posillico, Ph.D., President and Chief Executive Officer, commented on the appointment, "On behalf of Elusys' Board of Directors and management, I am very pleased to welcome Bob to our executive management team. As Vice President of Research, he will play a key role in helping to further develop and advance our corporate and scientific strategies. With more than twenty-five years of experience in developing monoclonal antibody-based products from both the biotech and pharmaceutical sectors, Dr. Gundel will lead our existing R&D team to further the development of our antibody based products for the treatment of infectious disease. He will also use his expertise to evaluate new product opportunities and will play a key leadership role in managing our existing and future R&D collaborations."

Prior to joining Elusys, Dr. Gundel held executive management positions at a number of leading biopharmaceutical companies including, Bayer, Chiron, XOMA and ARIUS. Most recently, Dr. Gundel served as Chief Scientific Officer at ARIUS Research, Inc., a biotechnology company focused on the discovery and development of therapeutic antibodies for the treatment of cancer and other diseases. At ARIUS, he managed the drug discovery and development programs and worked to broaden the company's targeted therapeutic areas by identifying and developing new programs outside of oncology. He also identified new technologies to keep the company ahead of the curve for therapeutic drug discovery, development and manufacturing.

Previously, Dr. Gundel was Vice President, Preclinical Research and Scientific Corporate Development at XOMA (US), LLC, a biote
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
2. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
3. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
4. ExonHit Therapeutics - 2007 Financial Results
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
7. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
8. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
9. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
10. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
11. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Ambassador to also Visit...er 24, 2009 -- , , ,Who: David Appia, French Ambas...nd CEO of the Invest in France Agency, , , , ,Wha...s to discuss recent pro-business initiatives adopt...cal and academic landscape for innovation and deve...
(Date:11/24/2009)..., , ST. LOUIS, Nov. 24 /PRNewswire-Firs... ) will be presenting at the NASDAQ OMX conference..., 7:45 AM US/CST. Interested parties may listen vi... at http://inve s tor.sig m a a ldrich.com... this file. ,, About Sigma-Aldrich: Sigma...
(Date:11/24/2009)..., , SHANGHAI, Nov. 24 /PRNewswire...tate Food & Drug Administration (SFDA) has app...D) for its oral insulin project,(Nodlin), an innov...IND,approval allows Biolaxy to initiate its first ...isorder characteristic of high blood glucose and p...
(Date:11/24/2009)..., , DUBLIN, November 24 /PRNewswire-F..., the global specialty biopharmaceutical company, ... European Medicines Agency for,velaglucerase alfa,...opment,for the treatment of Type 1 Gaucher disease...glucerase alfa that has been submitted, with previ...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
...isconsin Technology Network recently interviewed t...ut their work in games and education, and how the ...cademics. The first interview is with Dr. James Ge...ulum and Instruction in the School of Education at...Have to Teach Us About Learning and Literacy. Dr. ...
...ON Remember this summers property tax freeze budg...because they thought it was great politics; many o...icy and secretly hoped Doyle would veto it. , ,Tha...s proposal to raise the state minimum wage, which ...e for such a populist bill if it reaches the floor...
...ly 17th John Byrnes made the following statements ... Technology Network: Its time to get serious. It i...ne in traditional manufacturing jobs there is not...the manufacturing community. It is hard to read th...hat (1) our manufacturing industry is not worth sa...
Other Biology Technology:The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 2The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 3The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 4The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 5The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 6Doyle and the Legislature Have Much To Agree Upon When It Comes To The Economy 2Doyle and the Legislature Have Much To Agree Upon When It Comes To The Economy 3Let's Get Serious About Manufacturing! 2
(Date:11/26/2009)...Heidelberg, 27 November 2009 What are the bare es...quired to produce a cell that can survive on its o...l, and understand how an entire organism functions... that scientists in a partnership between the Euro...berg, Germany, and the Centre de Regulacio Genmica...
(Date:11/25/2009)...ns, Ga. Bacteria don,t have easy lives. In additi...gs, they have natural enemies called bacteriophage...ery two days. , Still, bacteria and another cla...red in extreme environments such as deep-sea volca...cause they have a built-in defense system that hel...
(Date:11/25/2009)... the course of a lifetime, the heart pumps some 25... order to do this, the muscle fibers of the heart ...eaded by Dr. Wolfgang Rottbauer, vice chair of the...ty Hospital (Chairman: Prof. Dr. H. A. Katus), has...stability of the smallest muscular unit, the sarco...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3New genetic cause of cardiac failure discovered 2National Investigational Trial for Emergency Stroke Care At CDH 3A One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours 5410 1National Investigational Trial for Emergency Stroke Care At CDH 3A One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours 5410 2National Investigational Trial for Emergency Stroke Care At CDH 3A One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours 5410 3New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 1New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 2U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 1U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 2U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 3
...s that survive chemotherapy leaving the door open...stitute scientists developed an original method fo...ells to reveal exactly how a chemotherapy drug aff...n, together with Naama Geva-Zatorsky and Eran Eden...olecular Cell Biology Department, the question pos...
...t you observe in another but have never actually e...ted brain-imaging technique to try and answer this...n the January 29th issue of the journal Neuron , ... empathy. , Brain-imaging studies have shown simi...their own emotions or observe the same emotions in...
...ronments for a Wide Range of Platforms , , SUNNY...s of America, Inc. , a leading supplier of innovat...peripherals and biometric security solutions, toda...logy to make its 2.5-inch encrypted hard disk driv...s (Opal SSC). Opal SSC is a new storage security s...
Other Biology News:Weizmann Institute scientists discover how cancer cells survive a chemotherapy drug 2I feel your pain: Neural mechanisms of empathy 2Fujitsu Develops HDD Security Technology Based on Opal SSC Standards 2Fujitsu Develops HDD Security Technology Based on Opal SSC Standards 3
Calcium Phosphate Transfection Kit from Invitrogen
Custom siRNA, HPLC purified from Ambion
Silencer Pre-designed siRNA, standard purity, annealed from Ambion
Minimal Essential Medium Alpha Medium (Custom) from Invitrogen
Biology Products: